Moll Wendén advises Calmark Sweden AB in an issue of units amounting to approximately SEK 26.1 million with preferential rights for existing shareholders.

If the rights issue is fully subscribed, the company will initially raise approximately SEK 26.1 million before deduction of costs related to the rights issue. Upon full subscription and exercise of the warrants included in the issued units for the subscription of B-shares, the Company will be provided additional funding of up to approximately SEK 13.1 million before deduction of costs related to the rights issue.

Calmark is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020.

In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited.

Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker.

Moll Wendén has acted as legal advisor to Calmark in connection with the rights issue.

For further information, please see Calmark’s press release here.

Moll Wendén’s team has mainly consisted of Henric Stråth (responsible partner), Mikaela Lenander and Alexander Blom Vigsø.